Drug Profile
SBRA 31012
Latest Information Update: 08 Apr 2003
Price :
$50
*
At a glance
- Originator Roswell Park Cancer Institute; State University of New York at Stony Brook
- Class Antineoplastics; Taxanes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 17 Jul 2001 This compound is still in active development
- 16 May 1997 Preclinical development for Cancer in USA (Unknown route)